Cargando…
Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice
Enzymatically stable and specific neuropeptide Y1 receptor (NPYR1) agonists, such as sea lamprey PYY(1-36) (SL-PYY(1-36)), are believed to improve glucose regulation in diabetes by targeting pancreatic islets. In this study, streptozotocin (STZ) diabetic transgenic Glu(CreERT2);ROSA26-eYFP and Ins1...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949013/ https://www.ncbi.nlm.nih.gov/pubmed/33716983 http://dx.doi.org/10.3389/fendo.2021.633625 |
_version_ | 1783663472434741248 |
---|---|
author | Lafferty, Ryan A. Tanday, Neil Moffett, R. Charlotte Reimann, Frank Gribble, Fiona M. Flatt, Peter R. Irwin, Nigel |
author_facet | Lafferty, Ryan A. Tanday, Neil Moffett, R. Charlotte Reimann, Frank Gribble, Fiona M. Flatt, Peter R. Irwin, Nigel |
author_sort | Lafferty, Ryan A. |
collection | PubMed |
description | Enzymatically stable and specific neuropeptide Y1 receptor (NPYR1) agonists, such as sea lamprey PYY(1-36) (SL-PYY(1-36)), are believed to improve glucose regulation in diabetes by targeting pancreatic islets. In this study, streptozotocin (STZ) diabetic transgenic Glu(CreERT2);ROSA26-eYFP and Ins1 (Cre/+);Rosa26-eYFP mouse models have been used to study effects of sustained NPYR1 activation on islet cell composition and alpha- and beta-cell lineage transitioning. STZ induced a particularly severe form of diabetes in Ins1 (Cre/+);Rosa26-eYFP mice, but twice-daily administration (25 nmol/kg) of SL-PYY(1-36) for 11 days consistently improved metabolic status. Blood glucose was decreased (p < 0.05 - p < 0.001) and both fasted plasma and pancreatic insulin significantly increased by SL-PYY(1-36). In both Glu(CreERT2);ROSA26-eYFP and Ins1 (Cre/+); Rosa26-eYFP mice, STZ provoked characteristic losses (p < 0.05 - p < 0.001) of islet numbers, beta-cell and pancreatic islet areas together with increases in area and central islet location of alpha-cells. With exception of alpha-cell area, these morphological changes were fully, or partially, returned to non-diabetic control levels by SL-PYY(1-36). Interestingly, STZ apparently triggered decreased (p < 0.001) alpha- to beta-cell transition in Glu(CreERT2);ROSA26-eYFP mice, together with increased loss of beta-cell identity in Ins1 (Cre/+);Rosa26-eYFP mice, but both effects were significantly (p < 0.001) reversed by SL-PYY(1-36). SL-PYY(1-36) also apparently reduced (p < 0.05) beta- to alpha-cell conversion in Ins1 (Cre/+);Rosa26-eYFP mice and glucagon expressing alpha-cells in Glu(CreERT2);ROSA26-eYFP mice. These data indicate that islet benefits of prolonged NPY1R activation, and especially restoration of beta-cell mass, are observed irrespective of diabetes status, being linked to cell lineage alterations including transdifferentiation of alpha- to beta-cells. |
format | Online Article Text |
id | pubmed-7949013 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79490132021-03-12 Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice Lafferty, Ryan A. Tanday, Neil Moffett, R. Charlotte Reimann, Frank Gribble, Fiona M. Flatt, Peter R. Irwin, Nigel Front Endocrinol (Lausanne) Endocrinology Enzymatically stable and specific neuropeptide Y1 receptor (NPYR1) agonists, such as sea lamprey PYY(1-36) (SL-PYY(1-36)), are believed to improve glucose regulation in diabetes by targeting pancreatic islets. In this study, streptozotocin (STZ) diabetic transgenic Glu(CreERT2);ROSA26-eYFP and Ins1 (Cre/+);Rosa26-eYFP mouse models have been used to study effects of sustained NPYR1 activation on islet cell composition and alpha- and beta-cell lineage transitioning. STZ induced a particularly severe form of diabetes in Ins1 (Cre/+);Rosa26-eYFP mice, but twice-daily administration (25 nmol/kg) of SL-PYY(1-36) for 11 days consistently improved metabolic status. Blood glucose was decreased (p < 0.05 - p < 0.001) and both fasted plasma and pancreatic insulin significantly increased by SL-PYY(1-36). In both Glu(CreERT2);ROSA26-eYFP and Ins1 (Cre/+); Rosa26-eYFP mice, STZ provoked characteristic losses (p < 0.05 - p < 0.001) of islet numbers, beta-cell and pancreatic islet areas together with increases in area and central islet location of alpha-cells. With exception of alpha-cell area, these morphological changes were fully, or partially, returned to non-diabetic control levels by SL-PYY(1-36). Interestingly, STZ apparently triggered decreased (p < 0.001) alpha- to beta-cell transition in Glu(CreERT2);ROSA26-eYFP mice, together with increased loss of beta-cell identity in Ins1 (Cre/+);Rosa26-eYFP mice, but both effects were significantly (p < 0.001) reversed by SL-PYY(1-36). SL-PYY(1-36) also apparently reduced (p < 0.05) beta- to alpha-cell conversion in Ins1 (Cre/+);Rosa26-eYFP mice and glucagon expressing alpha-cells in Glu(CreERT2);ROSA26-eYFP mice. These data indicate that islet benefits of prolonged NPY1R activation, and especially restoration of beta-cell mass, are observed irrespective of diabetes status, being linked to cell lineage alterations including transdifferentiation of alpha- to beta-cells. Frontiers Media S.A. 2021-02-25 /pmc/articles/PMC7949013/ /pubmed/33716983 http://dx.doi.org/10.3389/fendo.2021.633625 Text en Copyright © 2021 Lafferty, Tanday, Moffett, Reimann, Gribble, Flatt and Irwin http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Lafferty, Ryan A. Tanday, Neil Moffett, R. Charlotte Reimann, Frank Gribble, Fiona M. Flatt, Peter R. Irwin, Nigel Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice |
title | Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice |
title_full | Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice |
title_fullStr | Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice |
title_full_unstemmed | Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice |
title_short | Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice |
title_sort | positive effects of npy1 receptor activation on islet structure are driven by pancreatic alpha- and beta-cell transdifferentiation in diabetic mice |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949013/ https://www.ncbi.nlm.nih.gov/pubmed/33716983 http://dx.doi.org/10.3389/fendo.2021.633625 |
work_keys_str_mv | AT laffertyryana positiveeffectsofnpy1receptoractivationonisletstructurearedrivenbypancreaticalphaandbetacelltransdifferentiationindiabeticmice AT tandayneil positiveeffectsofnpy1receptoractivationonisletstructurearedrivenbypancreaticalphaandbetacelltransdifferentiationindiabeticmice AT moffettrcharlotte positiveeffectsofnpy1receptoractivationonisletstructurearedrivenbypancreaticalphaandbetacelltransdifferentiationindiabeticmice AT reimannfrank positiveeffectsofnpy1receptoractivationonisletstructurearedrivenbypancreaticalphaandbetacelltransdifferentiationindiabeticmice AT gribblefionam positiveeffectsofnpy1receptoractivationonisletstructurearedrivenbypancreaticalphaandbetacelltransdifferentiationindiabeticmice AT flattpeterr positiveeffectsofnpy1receptoractivationonisletstructurearedrivenbypancreaticalphaandbetacelltransdifferentiationindiabeticmice AT irwinnigel positiveeffectsofnpy1receptoractivationonisletstructurearedrivenbypancreaticalphaandbetacelltransdifferentiationindiabeticmice |